MX376266B - Particulas no replicantes derivadas de virus y sus usos. - Google Patents
Particulas no replicantes derivadas de virus y sus usos.Info
- Publication number
- MX376266B MX376266B MX2015008155A MX2015008155A MX376266B MX 376266 B MX376266 B MX 376266B MX 2015008155 A MX2015008155 A MX 2015008155A MX 2015008155 A MX2015008155 A MX 2015008155A MX 376266 B MX376266 B MX 376266B
- Authority
- MX
- Mexico
- Prior art keywords
- viruses
- replicating
- particles derived
- cells
- replicating particles
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title 1
- 230000003362 replicative effect Effects 0.000 abstract 3
- 230000010415 tropism Effects 0.000 abstract 2
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 230000001461 cytolytic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
- C12N2760/20263—Methods of inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261740856P | 2012-12-21 | 2012-12-21 | |
| US201361835310P | 2013-06-14 | 2013-06-14 | |
| PCT/CA2013/051009 WO2014094182A1 (en) | 2012-12-21 | 2013-12-20 | Non-replicating virus-derived particles and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015008155A MX2015008155A (es) | 2016-02-05 |
| MX376266B true MX376266B (es) | 2025-03-07 |
Family
ID=50977496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008155A MX376266B (es) | 2012-12-21 | 2013-12-20 | Particulas no replicantes derivadas de virus y sus usos. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11110138B2 (enExample) |
| EP (1) | EP2935569B1 (enExample) |
| JP (2) | JP6612619B2 (enExample) |
| KR (1) | KR102167497B1 (enExample) |
| CN (1) | CN105121636A (enExample) |
| AU (1) | AU2013362761B2 (enExample) |
| BR (1) | BR112015015045A8 (enExample) |
| CA (1) | CA2896162C (enExample) |
| CL (1) | CL2015001738A1 (enExample) |
| ES (1) | ES2745599T3 (enExample) |
| IL (1) | IL239486B (enExample) |
| MX (1) | MX376266B (enExample) |
| MY (1) | MY174912A (enExample) |
| PH (1) | PH12015501442A1 (enExample) |
| RU (1) | RU2705556C2 (enExample) |
| SG (2) | SG10201704903YA (enExample) |
| WO (1) | WO2014094182A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2896162C (en) * | 2012-12-21 | 2021-10-12 | Ottawa Hospital Research Institute | Non-replicating virus-derived particles and uses thereof |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN109985244A (zh) * | 2017-12-29 | 2019-07-09 | 广州威溶特医药科技有限公司 | E3连接酶抑制剂和溶瘤病毒在制备抗肿瘤药物的应用 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109432098B (zh) * | 2018-11-20 | 2021-04-13 | 天津大学 | 化合物ps-341在制备小rna病毒科肠道病毒属病毒抑制剂的应用 |
| EP3708176A1 (en) * | 2019-03-15 | 2020-09-16 | Centre National De La Recherche Scientifique -Cnrs- | Mutant vsv ectodomain polypeptide and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106619A (en) | 1983-12-20 | 1992-04-21 | Diamond Scientific Co. | Preparation of inactivated viral vaccines |
| IL153570A0 (en) | 2000-06-26 | 2003-07-06 | Wellstat Biologics Corp | Purging of cells using viruses |
| AU2003268505A1 (en) * | 2002-09-09 | 2004-03-29 | University Of Tennessee Research Foundation | Recombinatant mutants of rhabdovirus and methods of use thereof |
| JP4708027B2 (ja) | 2002-10-01 | 2011-06-22 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗癌組成物および抗感染疾患組成物ならびにこれらを使用する方法 |
| CN100579579C (zh) * | 2002-10-01 | 2010-01-13 | 诺华疫苗和诊断公司 | 抗癌及抗感染性疾病组合物及其使用方法 |
| EP2301573A1 (en) | 2002-10-01 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Anti-cancer and anti-infectious disease compositions and methods for using same |
| ES2319424T3 (es) | 2003-03-27 | 2009-05-07 | Ottawa Health Research Institute | Virus mutantes de la estomatitis vesivular y sus usos. |
| EP1726647B1 (en) * | 2004-03-19 | 2015-01-07 | GenomIdea, Inc. | Gene promoting vascular endothelial cell growth |
| US8703467B2 (en) * | 2004-05-27 | 2014-04-22 | Baxter International Inc. | Inactivation of a pathogen in a sample by a treatment with formalin and UV light |
| CA2921063C (en) | 2006-09-15 | 2020-01-28 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
| ES2532808T3 (es) | 2008-09-16 | 2015-03-31 | Genomidea Inc. | Agente terapéutico/profiláctico para cáncer de próstata |
| CN102858959B (zh) | 2009-12-10 | 2016-02-24 | 渥太华医院研究院 | 溶瘤弹状病毒 |
| RU2013139565A (ru) | 2011-01-27 | 2015-03-10 | Лентиджен Корпорейшн | Усовершенствованная праймерная и бустерная вакцина |
| CN103415797B (zh) * | 2011-02-02 | 2016-01-27 | 康宁光缆系统有限责任公司 | 适用于为设备机架中的光学底板建立光学连接的稠密光纤连接器总成及相关的连接器与缆线 |
| WO2012122649A1 (en) | 2011-03-15 | 2012-09-20 | Ottawa Hospital Research Institute | Recombinant orf virus |
| US9623096B2 (en) * | 2011-11-09 | 2017-04-18 | Celverum Inc. | Virally infected hematopoietic cells and uses thereof |
| CA2896162C (en) * | 2012-12-21 | 2021-10-12 | Ottawa Hospital Research Institute | Non-replicating virus-derived particles and uses thereof |
-
2013
- 2013-12-20 CA CA2896162A patent/CA2896162C/en not_active Expired - Fee Related
- 2013-12-20 KR KR1020157019923A patent/KR102167497B1/ko not_active Expired - Fee Related
- 2013-12-20 JP JP2015548131A patent/JP6612619B2/ja not_active Expired - Fee Related
- 2013-12-20 AU AU2013362761A patent/AU2013362761B2/en not_active Ceased
- 2013-12-20 CN CN201380071341.1A patent/CN105121636A/zh active Pending
- 2013-12-20 SG SG10201704903YA patent/SG10201704903YA/en unknown
- 2013-12-20 ES ES13865170T patent/ES2745599T3/es active Active
- 2013-12-20 SG SG11201504843UA patent/SG11201504843UA/en unknown
- 2013-12-20 MY MYPI2015702052A patent/MY174912A/en unknown
- 2013-12-20 RU RU2015128766A patent/RU2705556C2/ru active
- 2013-12-20 BR BR112015015045A patent/BR112015015045A8/pt not_active Application Discontinuation
- 2013-12-20 EP EP13865170.8A patent/EP2935569B1/en active Active
- 2013-12-20 WO PCT/CA2013/051009 patent/WO2014094182A1/en not_active Ceased
- 2013-12-20 US US14/654,259 patent/US11110138B2/en not_active Expired - Fee Related
- 2013-12-20 MX MX2015008155A patent/MX376266B/es active IP Right Grant
-
2015
- 2015-06-17 IL IL239486A patent/IL239486B/en active IP Right Grant
- 2015-06-18 CL CL2015001738A patent/CL2015001738A1/es unknown
- 2015-06-19 PH PH12015501442A patent/PH12015501442A1/en unknown
-
2019
- 2019-09-11 JP JP2019165067A patent/JP2020014467A/ja active Pending
-
2021
- 2021-07-21 US US17/382,146 patent/US20210346441A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11110138B2 (en) | 2021-09-07 |
| US20210346441A1 (en) | 2021-11-11 |
| JP2020014467A (ja) | 2020-01-30 |
| RU2705556C2 (ru) | 2019-11-07 |
| CN105121636A (zh) | 2015-12-02 |
| IL239486B (en) | 2019-08-29 |
| AU2013362761A1 (en) | 2015-07-16 |
| EP2935569B1 (en) | 2019-05-01 |
| HK1210624A1 (en) | 2016-04-29 |
| EP2935569A1 (en) | 2015-10-28 |
| MY174912A (en) | 2020-05-21 |
| KR20150112957A (ko) | 2015-10-07 |
| WO2014094182A1 (en) | 2014-06-26 |
| SG11201504843UA (en) | 2015-07-30 |
| NZ709439A (en) | 2020-09-25 |
| JP2016501538A (ja) | 2016-01-21 |
| KR102167497B1 (ko) | 2020-10-20 |
| US20150320810A1 (en) | 2015-11-12 |
| PH12015501442A1 (en) | 2015-09-14 |
| CL2015001738A1 (es) | 2015-12-18 |
| BR112015015045A8 (pt) | 2018-01-23 |
| JP6612619B2 (ja) | 2019-11-27 |
| RU2015128766A (ru) | 2017-01-26 |
| CA2896162A1 (en) | 2014-06-26 |
| MX2015008155A (es) | 2016-02-05 |
| ES2745599T3 (es) | 2020-03-02 |
| EP2935569A4 (en) | 2016-08-03 |
| IL239486A0 (en) | 2015-07-30 |
| SG10201704903YA (en) | 2017-07-28 |
| CA2896162C (en) | 2021-10-12 |
| AU2013362761B2 (en) | 2019-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3256594T3 (pl) | Ulepszone dostarczanie cząstek wirusa do prążkowia i kory | |
| MX376266B (es) | Particulas no replicantes derivadas de virus y sus usos. | |
| SG10201807208RA (en) | Viral resistant cells and uses thereof | |
| EP3697820A4 (en) | PROCEDURES AND COMPOSITIONS RELATED TO MANIPULATED REGULATORY T-CELLS | |
| UY34875A (es) | Purificación de partículas tipo virus | |
| MX2016000381A (es) | Particula tipo virus que comprende antigeno de muerte celular programada 1 o antigeno de ligando de muerte celular programada 1. | |
| IL288233A (en) | Modified viral particles and their use | |
| MX2020005187A (es) | Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos. | |
| EA201791460A1 (ru) | N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения | |
| TR201900124T4 (tr) | Dispersiyon Reçineleri | |
| EP2753355A4 (en) | ONCOLYTIC HERPES SIMPLEX VIRUS AND THERAPEUTIC USES THEREOF | |
| UA118189C2 (uk) | 4-аміно-6-(4-заміщені-феніл)-піколінати і 6-аміно-2-(4-заміщені-феніл)-піримідин-4-карбоксилати і їхнє застосування як гербіцидів | |
| WO2017211371A3 (en) | Calr and jak2 vaccine compositions | |
| EP2928900A4 (en) | GUANIDIN-FUNCTIONALIZED PARTICLES AND METHOD OF PREPARATION AND USE | |
| IL255944A (en) | Carbohydrate-modified particles and particulate formulations for modulating an immune response | |
| IN2014MN01911A (enExample) | ||
| EP3368547A4 (en) | CHIMERIC RSV, IMMUNOGENIC COMPOSITIONS AND METHOD FOR USE THEREOF | |
| EA201501066A1 (ru) | Классификатор | |
| MX2017000437A (es) | Ensamble de pesca de liberacion rapida. | |
| FR3017291B1 (fr) | Billes de cellulose exfoliantes et utilisations cosmetiques de celles-ci | |
| EP3102613A4 (en) | Polymer particles and uses thereof | |
| WO2016119052A8 (en) | Compositions and methods for enhancing oncolytic virus efficacy | |
| EP3664846A4 (en) | ANTIBODIES AGAINST THE EPSTEIN-BARR VIRUS AND ITS USES | |
| MX2017002768A (es) | Agentes antivirales y usos de los mismos. | |
| EP3102590A4 (en) | Antigenic epitopes from ebv gp350/220 and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: CELVERUM INC. |
|
| FG | Grant or registration |